Ariana Boswell

All articles by Ariana Boswell

• Sarepta shares plans to improve safety of Elevidys

  Following two fatal cases of acute liver failure associated with ELEVIDYS, Sarepta is taking steps to improve the safety of the drug.

• REGENXBIO shares positive findings from DMD gene therapy trial

  Preliminary results from the AFFINITY DUCHENNE trial show that the gene therapy RGX-202 improves functional performance in patients with DMD.

• Novel metabolism-targeting drug may improve DMD symptoms

  A recent study found that a mouse model of DMD treated with a novel enzyme inhibitor exhibited improvements in muscle function.

• The changing landscape of exon-skipping therapies for DMD

  Pharmaceutical companies provided updates on their exon skipping therapies for DMD at the CureDuchenne 2025 FUTURES National Conference.

• Study finds general public is willing to fund DMD treatment

  A recent study found that members of the general public are willing to pay increased taxes to cover the costs of a novel DMD treatment.

• Long-term cardiac effects of glucocorticoids in DMD uncertain

  A recent literature review of the effects of glucocorticoid therapy on cardiovascular health in patients with DMD showed mixed findings.

• Review examines risks of general anesthesia, neuromuscular blocking agents in DMD

  A recent systematic review highlighted the risks associated with various anesthetic techniques in patients with DMD.

• Long-term DMD may lead to heart, lung and bone complications

  A recent study used administrative health records to follow patients with DMD long-term and assess key clinical outcomes.

• Children with DMD may have difficulty socializing with peers

  Researchers found that children with DMD may have reduced social cognition, an understudied element of neuropsychological function.

• Review details safety and efficacy of current DMD treatments

  A recent review article explores the expanding therapeutic landscape for Duchenne muscular dystrophy (DMD).